The U.S. government claims that Tylenol's active ingredient, acetaminophen, is related to autism
According to a September 21 report by The Washington Post, four anonymous insiders revealed that the U.S. government will release a statement on the 22nd claiming that the active ingredient in one of the world's most widely used drugs, Tylenol (Tylenol), acetaminophen (acetaminophen), may have a potential link with autism.
On September 21, Trump disclosed this move at Charlie Kirk's memorial event, which is expected to be officially announced at a White House press conference.
He said: "Tomorrow we will make a major announcement... I think this is a milestone event in the history of medical care in our country. I believe you will find it incredible, and we seem to have found a solution to autism."
The National Institutes of Health will also announce on the 22nd that it has formally launched data research related to autism, with 13 research teams receiving scientific funding to study the causes and treatments of autism and to verify previous research findings.
Two people who know the content of the announcement to be released on the 22nd revealed that the U.S. Health Secretary Kennedy has listed autism as a core issue in the "Make America Healthy Again" agenda.
Insiders said that U.S. federal health officials will warn pregnant women to avoid using the drug unless they have a fever. Because some studies suggest that using Tylenol in early pregnancy may be associated with an increased risk of autism in children.
In addition to warning about the risks of Tylenol, U.S. officials are also planning to promote a drug called folic acid, claiming it may become a treatment for autism. Folic acid is usually used to relieve side effects of certain drugs and to treat vitamin B9 deficiency. In early double-blind, placebo-controlled trials involving children with autism, significant improvements were observed in the children's language expression and comprehension after administration of folic acid.
U.S. Food and Drug Administration officials have recently been reviewing relevant statements regarding the use of this drug.
Tylenol is a brand under Johnson & Johnson (now part of the spun-off Kenvue). Kenvue's interim CEO Kirk Perry privately urged U.S. Health Secretary Kennedy not to list Tylenol as a cause of autism.
The company's spokesperson stated in a statement to Politico that they strongly oppose any claims linking Tylenol to autism, stating that preventing women from using Tylenol would force them to make a "dangerous choice" between persistent pain and painkillers with higher risks.
The spokesperson said that the facts are that after more than a decade of rigorous research, top medical professionals and global health regulatory agencies have confirmed that there is no credible evidence linking acetaminophen to autism. The company said that they will stand with numerous public health and medical professionals who have reached a consensus through scientific research, continuing to explore all options to protect the health interests of American women and children.
Over the past few weeks, executives of the Tylenol manufacturer have met with the U.S. government to express concerns about the federal government's initiative and discuss subsequent measures.
It was reported that President Trump has long been concerned about the rising incidence of autism in the United States and has assigned personnel to find solutions this year.
Health Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, NIH Director Jay Bhattacharya, and other senior officials participated in the program.
Kennedy had previously stated during a televised cabinet meeting in April: "We have launched a large-scale testing and research program, with hundreds of scientists from around the world participating. By September, we will identify the epidemiological causes of autism and find ways to eliminate the causative factors."
This statement raised concerns among many researchers, who said that such research typically requires a long process to be conducted accurately.
Over the past few decades, the rate of autism diagnosis in U.S. children has continued to rise. Surveys by the Centers for Disease Control and Prevention in certain communities show that the prevalence of autism in 8-year-old children has reached 1 in 31, compared to approximately 1 in 150 in 2000.
The reasons for the sharp increase in autism diagnoses remain widely controversial and have not yet been determined. Improvements in detection methods and increased public awareness are some of the reasons, but many researchers believe that in addition to the over 100 genes already linked to autism, there may be other factors, possibly related to the living environment or lifestyle of Americans.
Original: www.toutiao.com/article/1844014583055627/
Statement: This article represents the views of the author.